Scorpion Capital · activist-deck
Soleno Therapeutics (SLNO)
415 pages · 0 arc beats · 0 loops
Soleno Therapeutics (SLNO)
Scorpion Capital · 2025-08 arc beats above · slides in the middle · loops below · scroll → 0 LOOPS
120406080100120140160180200220240260280300320340360380400415
Deck intelligence map
1 coverage by narrative range · generated from this deck JSON
Narrative range 415 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Whole deck 415 slides 100% 415/415 slides 100% 415/415 slides · 2643 hits — 0/415 slides
2.9% 12/415 slides · 14 hits 56.6% 235/415 slides · 236 hits — 0/415 slides
— 0/415 slides
Slide inventory
415 every slide · same image gating as the playbook
01
This is a classic activist short-seller cover page, utilizing aggressive, emotionally charged language to frame the thesis.front_matter
03
The slide uses anonymous expert testimony to undermine the company's clinical trial integrity and market prospects.expose_contradiction
04
The slide uses a direct user testimonial to highlight product safety concerns.illustrate_case
05
The slide presents anecdotal evidence of medical side effects to support an activist narrative.illustrate_case
06
The slide uses a social media post as a testimonial to highlight negative patient outcomes.illustrate_case
07
The slide uses a screenshot of a Facebook post to undermine the clinical trial results of the drug VYKAT.expose_contradiction
09
The slide functions as a summary of the 'villain' or 'expose' narrative arc of the deck.summarize
10
The slide uses a list-based structure to summarize key arguments against the company.summarize
11
The slide uses inflammatory language ('smelled a rat', 'drop like flies') to frame the company and investigator as negligent.name_villain
12
Uses social media screenshots as primary evidence to build a case against the drug's safety profile.expose_contradiction
13
Uses anecdotal evidence from Facebook groups to build a case for systemic safety issues.expose_contradiction
14
The slide uses a specific social media post as a case study to infer broader safety concerns.expose_contradiction
15
Uses a screenshot of a Facebook group post as primary evidence to support the claim of medical danger.expose_contradiction
16
Uses direct quotes from Facebook posts to highlight patient safety concerns.expose_contradiction
17
The slide highlights a discrepancy between the FDA label's explicit warnings about DKA and the company's omission of this risk in their phase 3 and open-label mexpose_contradiction
18
The slide uses a Q&A format to build a case for the 'two-hit' hypothesis regarding drug interactions.illustrate_case
19
The slide uses a combination of narrative description and citations of medical literature to establish the 'villain' (diazoxide) as dangerous.name_villain
20
The slide uses direct excerpts from a medical paper to build a case against the drug's safety profile.expose_contradiction
21
The slide uses a direct quote from the Pediatric Endocrine Society guidelines to expose the company's failure to address known side effects in their trial desigexpose_contradiction
22
The slide uses a direct quote from a medical paper to expose the ineffectiveness of the company's recommended treatment.expose_contradiction
23
The slide uses direct quotes from a KOL to build a case against the safety of a drug (Vykat) in the context of PWS.expose_contradiction
24
The slide uses a combination of medical argumentation and cited conclusions to build a case against a specific treatment protocol.preempt_rebuttal
25
Uses emotional appeal and visual evidence to highlight the difficulty of diagnosing edema in PWS patients.diagnose_problem
26
The slide uses anecdotal evidence from online discussion groups to highlight patient safety concerns.illustrate_case
27
The slide uses screenshots of Facebook group discussions to provide anecdotal evidence of adverse drug reactions.illustrate_case
28
The slide uses screenshots of Facebook group posts as primary evidence of adverse drug reactions.expose_contradiction
29
Uses patient testimonials as primary evidence to challenge the safety profile of the drug.expose_contradiction
30
The slide uses direct quotes from Facebook groups to undermine the product's safety/efficacy narrative.expose_contradiction
31
The slide uses direct quotes from a Facebook discussion group to highlight the patient/caregiver pain point of symptom detection.illustrate_case
32
The slide uses social media engagement (comment counts) as a proxy for negative sentiment and community concern.expose_contradiction
33
Uses a CEO quote to highlight a potential contradiction between management narrative and market reality.expose_contradiction
34
The slide uses a screenshot of a Soleno clinical trial flow diagram to highlight patient drop-off.expose_contradiction
35
The slide uses a Q&A transcript format to build a narrative of a cover-up regarding drug safety.expose_contradiction
36
The slide uses a Q&A format to highlight potential corporate malfeasance regarding clinical trial safety reporting.expose_contradiction
37
The slide uses a 'villain' narrative by framing patient advocacy groups as manipulators of the regulatory process.expose_contradiction
38
The slide uses an excerpt from the FDA label to critique the clinical trial design.expose_contradiction
39
The slide uses a red box to highlight a specific time period in the C602-RWP study to question the validity of the efficacy results.expose_contradiction
40
The slide uses a combination of narrative summary and direct Q&A transcript excerpts to build a case of potential clinical trial misconduct.expose_contradiction
41
The slide uses a 'villain' framing to question the validity of Soleno Therapeutics' clinical trial results.expose_contradiction
42
The slide uses a Q&A format to highlight internal skepticism regarding clinical trial data.expose_contradiction
43
The slide uses a 'quote-highlight' structure to emphasize specific allegations of misconduct.expose_contradiction
44
The slide uses a Q&A format to present whistleblower testimony.expose_contradiction
45
The slide uses strong, accusatory language ('hoax', 'scientifically unfounded', 'misleading') to attack the target company's scientific rationale.expose_contradiction
46
The slide uses a causal chain argument to refute a competitor's (Soleno) mechanism of action.expose_contradiction
47
The slide uses screenshots of social media posts as primary evidence to challenge the clinical narrative.expose_contradiction
48
The slide uses a specific chart from a clinical paper to challenge the safety profile of the drug.expose_contradiction
49
Uses a red-annotated chart to highlight the discrepancy between reported LBM and suspected fluid retention.expose_contradiction
50
Includes links to cached PDF documents as evidence of data discrepancy.expose_contradiction
51
The slide uses visual evidence to argue for data fabrication in a clinical trial report.expose_contradiction
52
The slide uses a 'smoking gun' narrative to allege data fabrication by comparing two sets of longitudinal clinical trial data.expose_contradiction
54
The slide emphasizes the credibility of the interviewees by linking them to specific published papers (C601 and C602).summarize
55
The slide uses a 'villain_critique' approach by leveraging an expert's authority to discredit the company's product.name_villain
56
The slide uses direct quotes from an expert to highlight risks of cardiac events, seizures, and trial design flaws.name_villain
57
The slide uses direct quotes from an expert to undermine the viability of the company's drug formulation.expose_contradiction
58
This slide functions as a 'villain_critique' or 'expose_contradiction' regarding the drug's clinical reception.introduce_nominees
60
The slide uses direct quotes from an expert to discredit a competitor's clinical trial results.name_villain
61
This slide presents expert testimony/critique from a trial investigator, serving as a 'villain_critique' or 'expose_contradiction' style slide.introduce_nominees
62
The slide uses a 'nominee_bio' structure to present a 'villain_critique' or 'expose_contradiction' narrative.introduce_nominees
63
The slide uses direct quotes to expose potential data omissions and competitive disadvantage.introduce_nominees
64
The slide uses direct quotes from an expert to undermine the commercial viability and clinical efficacy of the drug.introduce_nominees
65
The slide uses direct quotes from a trial investigator to undermine the drug's efficacy and safety profile.expose_contradiction
66
This slide is part of a series of 'investigator' profiles used to build a case against a company's clinical trial results.introduce_nominees
67
The slide presents critical expert feedback on drug formulation and safety protocols.introduce_nominees
68
The slide uses a 'villain' or 'expert critic' framing to undermine the credibility of a clinical trial and its associated drug.name_villain
69
The slide uses direct quotes from an expert to undermine the value proposition of the subject company's product.expose_contradiction
70
The slide uses a series of bullet points to contrast public posturing with private admissions.expose_contradiction
71
The slide uses specific quotes from an investigator to undermine the validity of clinical trial results and highlight potential adverse events.expose_contradiction
73
The slide emphasizes the credibility and breadth of the expert sample to validate the subsequent findings.summarize
74
The slide uses direct quotes to undermine the credibility of the drug's approval and market demand.expose_contradiction
75
The slide uses direct quotes from an expert consultation to undermine the company's product launch and clinical efficacy claims.introduce_nominees
76
The slide uses a direct quote to highlight medical risks that could limit the drug's market potential.expose_contradiction
77
The slide serves as a negative testimonial/expert critique of the product.introduce_nominees
78
The slide uses direct quotes to highlight a lack of industry awareness and clinical skepticism regarding the drug's mechanism and efficacy.expose_contradiction
79
The slide uses direct quotes to highlight the expert's negative sentiment and lack of awareness/enthusiasm for the drug.expose_contradiction
80
The slide highlights the risk of off-label substitution for the product.illustrate_case
81
The slide captures qualitative feedback from a medical expert, highlighting low adoption rates and negative sentiment toward the company's sales approach.introduce_nominees
82
The slide uses direct quotes to undermine the company's marketing claims and highlight physician concerns regarding side effects like diabetes.expose_contradiction
83
The slide uses direct quotes from an expert to undermine the company's clinical narrative.expose_contradiction
84
The slide uses direct quotes to undermine the company's marketing claims about drug efficacy and differentiation.expose_contradiction
85
The slide uses direct quotes to highlight the physician's lack of confidence in the drug and his perception of external pressure from patient advocacy groups.introduce_nominees
86
The slide uses direct quotes to undermine the credibility of the drug's clinical narrative and the company's influence on investigators.expose_contradiction
87
The slide uses direct quotes to validate the activist's thesis regarding the drug's risks and market limitations.illustrate_case
88
The slide highlights the gap between physician prescribing behavior (driven by patient pressure) and their actual clinical belief in the product.expose_contradiction
89
This slide presents qualitative interview data from a medical expert to undermine the credibility of a drug and a key opinion leader.introduce_nominees
90
The slide uses direct quotes to frame the expert's skepticism regarding the company's marketing and clinical rationale.introduce_nominees
91
The slide uses direct quotes to highlight expert skepticism regarding safety, efficacy, and pricing.expose_contradiction
92
The slide presents qualitative expert feedback from a medical professional regarding drug safety concerns.introduce_nominees
93
The slide presents qualitative feedback from a medical expert, highlighting concerns about diabetes risk and comparing the drug to the Aduhelm controversy.introduce_nominees
94
This slide presents qualitative feedback from a medical expert, highlighting significant barriers to adoption for the drug Vykat.illustrate_case
96
The slide presents a qualitative critique from a medical professional, highlighting skepticism regarding clinical efficacy and administrative burden.introduce_nominees
97
The slide uses direct quotes to undermine the clinical value and safety profile of the drug.expose_contradiction
98
The slide uses a direct quote to highlight the physician's negative sentiment regarding the drug's value proposition versus the administrative effort required.expose_contradiction
99
The slide uses direct quotes to highlight the expert's negative sentiment and concerns regarding side effects and reimbursement.introduce_nominees
100
The slide uses a direct quote to undermine the value proposition of the drug Vykat by highlighting the availability of cheaper alternatives.expose_contradiction
101
The slide uses direct quotes to expose contradictions in the drug's adoption and safety profile.introduce_nominees
102
The slide uses direct quotes to support the thesis that generic substitution is likely and that GLP-1s are effective.illustrate_case
104
The seesaw diagram is a visual metaphor for the mechanism of action and its unintended side effects.expose_contradiction
105
The slide uses a direct comparison of drug mechanisms to challenge the target company's safety claims.expose_contradiction
106
The red box in the image highlights the specific rows in the table that the author claims are being used to obfuscate the diabetes signal.expose_contradiction
107
The slide uses red boxes to draw attention to the specific data points being compared.expose_contradiction
108
The slide uses a screenshot of an FDA Medication Guide to contrast with the claim that DKA is missing from clinical literature.expose_contradiction
109
The slide uses direct quotes from medical experts to highlight a potential flaw in the company's clinical approach.expose_contradiction
110
The slide uses a Q&A transcript format to highlight specific patient cases that suggest a severe, long-term adverse effect.expose_contradiction
111
The slide uses a combination of narrative summary and a Q&A transcript excerpt to build a case against the company's clinical trial transparency.expose_contradiction
112
The slide uses a combination of narrative accusation and technical definitions to frame the company's data as obfuscated.expose_contradiction
113
The slide is a reproduction of a scientific poster (Gevers et al., 2024) used as evidence for clinical trial outcomes.analyze_data
114
The red box highlights the specific data point (Week 0 to Week 13) where the pooling occurs.expose_contradiction
115
The slide uses a red box and annotations to highlight the drop in sample size (n=125 to n=103) at week 13, suggesting data manipulation.expose_contradiction
116
The slide uses a red box and arrow to draw attention to the increase in HbA1c between week 0 and week 13.expose_contradiction
117
The slide uses a line chart with error bars to argue that the mean value hides adverse patient outcomes. It highlights the 1-standard deviation range and extrapexpose_contradiction
118
The slide explicitly notes the re-graphing of data from a previous page to improve numerical accuracy on the time axis and clarity of standard deviation ranges.analyze_data
119
The slide uses a red box to highlight the specific comparison between placebo and pooled data at week 13.expose_contradiction
120
The slide uses a red box to highlight the specific data columns that demonstrate the increase in pre-T2D and T2D patient populations.expose_contradiction
121
The slide uses a direct quote from a medical paper to highlight a discrepancy between the company's claim and the reported data.expose_contradiction
122
The slide uses red arrows and dots to visually demonstrate the discrepancy between cited data and the actual study graph.expose_contradiction
123
The slide uses a scatter plot with a linear regression line to refute a specific company claim regarding metabolic safety.expose_contradiction
124
The slide uses a red box to highlight the specific claim about 60% of participants having PD/DM at baseline.expose_contradiction
125
The slide uses a red oval to highlight the baseline data point and a dashed red box to represent the pre-T2D threshold range.expose_contradiction
126
The slide uses a direct quote from a conference abstract to highlight a discrepancy between the reported 60% figure and the author's own analysis.expose_contradiction
127
The slide uses a red box to highlight specific text in the source material to support the claim of burying data.expose_contradiction
128
The slide highlights a 'cut-and-paste' error where the visual structure of the graph is identical between two sources, but the underlying data points (HbA1c valexpose_contradiction
129
The slide uses visual annotations (red arrows and brackets) to highlight data manipulation.expose_contradiction
130
The slide uses a line chart with error bars to compare 'Original Data' vs 'New Data' to highlight data manipulation.expose_contradiction
131
Uses a 'before-after' comparison to highlight data inconsistency as evidence of fraud.expose_contradiction
132
The slide uses a line chart to demonstrate that the fasting glucose values are identical to a previous study (Miller et al 2024), implying the new HbA1c claims expose_contradiction
133
The slide highlights that GH induces insulin resistance while DCCR blocks insulin release, creating a synergistic risk for hyperglycemia.expose_contradiction
134
The slide uses a direct quote and an abstract excerpt to build credibility for the argument that GH therapy has negative metabolic consequences.cite_precedent
135
The slide uses direct excerpts from the FDA label to contrast with the company's reported clinical findings.expose_contradiction
136
The slide uses a 'two-hit' metaphor to describe the synergistic risk of the two medications.illustrate_case
138
The slide uses a list of 6 risk factors to build a medical case for why the drug's side effects are particularly dangerous for this specific patient group.expose_contradiction
139
The slide uses a combination of a table excerpt and a text excerpt to highlight a specific reporting discrepancy.expose_contradiction
140
Uses red boxes and arrows to visually connect the contradictory data points.expose_contradiction
141
The red box highlights the 30.4% peripheral edema rate. The text argues that the conflation of data between the P3 study and the extension study is an intentionexpose_contradiction
142
The slide uses medical definitions to frame the clinical trial results as evidence of adverse effects (edema) related to the drug DCCR.expose_contradiction
143
The slide uses a causal chain structure to explain the side effect.expose_contradiction
144
The slide uses a medical illustration to show the impact of fluid retention on heart chambers (diastolic vs systolic).diagnose_problem
145
The slide uses red annotations to re-interpret the company's original chart data.expose_contradiction
146
The slide uses a technical explanation of DEXA limitations to undermine the company's reported clinical trial results.expose_contradiction
147
The slide uses a table to highlight inconsistencies in clinical trial data to suggest misclassification of medical outcomes.expose_contradiction
148
The slide uses a table to map shared mechanisms of edema between GH and Diazoxide, and a second table to highlight the high prevalence of GH use in the P3 studyexpose_contradiction
149
The slide uses red boxes to highlight specific text in the protocol that contradicts the lack of reporting in the final study.expose_contradiction
150
The slide uses a direct quote from a physician to undermine the company's marketing claims.expose_contradiction
151
The slide uses expert testimony to highlight a potential safety concern (edema) and suggests the company is downplaying or managing it in an unusual way.expose_contradiction
152
The slide uses direct quotes from a KOL to build a case against the safety of a drug (Vykat) in the PWS population.preempt_rebuttal
153
The slide uses a combination of medical argumentation and cited research conclusions to highlight the risks of a specific drug regimen.expose_contradiction
154
The slide uses direct quotes from pediatric endocrinologists to highlight safety concerns, specifically referencing the drug's potential to exacerbate existing expose_contradiction
155
The slide uses Q&A transcripts to expose the risks associated with the drug.expose_contradiction
156
This appears to be a slide from a larger activist deck, likely part of a list of grievances or evidence against a company.name_villain
157
Uses social media follower counts as a proxy for community size to highlight the lack of engagement with the drug.expose_contradiction
158
The slide highlights the discrepancy between the expected community interest and the actual low membership/activity numbers.expose_contradiction
159
The slide uses a specific Facebook post as a case study to contradict the product's efficacy claims.expose_contradiction
160
The slide uses screenshots of Facebook comments to build a case against the drug's efficacy and safety profile.expose_contradiction
161
The slide uses anecdotal evidence from Facebook groups to highlight negative side effects (hyperphagia, behavioral changes) associated with the drug VYKAT.illustrate_case
162
The slide uses screenshots of Facebook posts to provide qualitative evidence of patient dissatisfaction and safety concerns.expose_contradiction
163
The slide uses direct quotes from Facebook groups to build a case against the drug's efficacy/safety profile.expose_contradiction
164
The slide uses screenshots of Facebook comments to illustrate the divide between frustrated participants and those defending the study.expose_contradiction
165
The slide uses social media screenshots to establish a pattern of adverse events.diagnose_problem
166
The slide uses anecdotal evidence from Facebook discussion groups to highlight potential adverse drug reactions.illustrate_case
167
The slide uses screenshots of Facebook group posts to provide anecdotal evidence of drug side effects.expose_contradiction
168
The slide uses patient testimonials to contradict the safety profile of the drug Vykat.expose_contradiction
169
The slide uses direct quotes from Facebook discussion groups to build a case against the drug's safety profile.illustrate_case
170
The slide uses direct quotes from a Facebook discussion group to highlight a patient/caregiver pain point regarding medical monitoring.diagnose_problem
171
The slide uses anecdotal evidence from Facebook groups to challenge the safety profile of the drug Vykat.expose_contradiction
172
The slide uses anecdotal evidence from Facebook groups to challenge the safety profile of the drug Vykat.expose_contradiction
173
The slide uses anecdotal evidence from social media to undermine the perceived value of the drug.expose_contradiction
174
The slide uses anecdotal evidence from Facebook groups to argue against the efficacy of a treatment by highlighting inconsistencies in user reports.expose_contradiction
175
The slide presents a skeptical analysis of patient/parent testimonials to undermine the perceived efficacy of a drug.expose_contradiction
176
The slide uses social media screenshots to undermine the credibility of a key proponent (Dr. Miller) by showing her own followers are skeptical of the product.expose_contradiction
177
The slide uses anecdotal evidence from Facebook groups to highlight patient dissatisfaction and side effects.illustrate_case
178
The slide uses direct quotes from Facebook group members to undermine the perceived efficacy and novelty of the drug.expose_contradiction
179
The slide uses anecdotal evidence from Facebook groups to illustrate a safety and compliance issue with the medication's delivery mechanism.diagnose_problem
180
The slide uses screenshots of Facebook group discussions to highlight negative patient experiences.expose_contradiction
181
The slide uses screenshots of Facebook group discussions to highlight patient/caregiver concerns that may contradict or exceed official side effect reporting.expose_contradiction
183
The slide uses a process diagram to illustrate the clinical trial flow, highlighting the transition from the failed C601 trial to the C602 withdrawal study.expose_contradiction
184
The slide uses an excerpt from an FDA label to critique the clinical trial evidence supporting a drug's efficacy.expose_contradiction
185
The slide uses a red box to highlight the specific data points (weeks 12-16 of the withdrawal period) that the author claims are the basis for the company's effexpose_contradiction
186
The slide uses a Q&A format to present evidence of potential trial manipulation.expose_contradiction
187
The slide uses a Q&A format to highlight potential data manipulation or questionable internal confidence in clinical trial results.expose_contradiction
188
The slide uses a 'quote-highlight' structure to emphasize specific allegations of misconduct.expose_contradiction
189
The slide uses a Q&A format to present qualitative evidence of investigator misconduct.expose_contradiction
190
The slide uses a 'show, don't tell' approach by presenting the actual questionnaire items to demonstrate their inherent subjectivity.expose_contradiction
191
The slide uses direct quotes from investigators to undermine the clinical trial results.expose_contradiction
192
The slide uses a Q&A format to present expert testimony regarding trial unblinding.expose_contradiction
193
The slide serves as a summary of deeper investigative findings regarding clinical trial data integrity.expose_contradiction
194
Focuses on trial design bias and potential data suppression.expose_contradiction
196
Includes chemical structures of Diazoxide and Choline to illustrate the 'salt' formulation.preempt_rebuttal
197
Includes screenshots of FDA Orange Book data and the front page of US Patent 7,572,789.expose_contradiction
198
The slide lists four specific US patents to support the claim of weakness.preempt_rebuttal
199
The slide uses a red arrow to point from the summary list to the specific boxed text in the FDA label excerpt.expose_contradiction
200
The slide serves as a product landscape overview to contrast current market offerings with the subject drug (Vykat).establish_context
201
The slide uses a 'before-after' or 'comparison' logic to undermine the pricing power of the target company (Vykat) by highlighting readily available, cheaper alexpose_contradiction
202
The slide uses a 'zoom-in' callout technique to highlight a specific claim in a scientific poster and then critiques the lack of supporting evidence for that clexpose_contradiction
203
The slide uses a screenshot of a video to contrast the company's public claims with the underlying data source.expose_contradiction
204
The slide uses a forensic approach to discredit clinical data, specifically targeting the validity of a poster presentation.expose_contradiction
205
The slide uses annotated charts to highlight alleged data manipulation in a clinical study.expose_contradiction
206
The slide uses a visual callout (yellow box) to highlight the specific data column in the table that contradicts the plotted graph.expose_contradiction
207
The slide presents a Q&A transcript excerpt highlighting potential fraud and competitive threats.expose_contradiction
208
The slide uses a line chart to visually debunk a competitor's claim about drug absorption kinetics.expose_contradiction
209
Uses a pharmacokinetic chart to illustrate the mechanism of XR vs immediate release to debunk the necessity of the company's product.expose_contradiction
210
The slide uses two charts to illustrate why XR is ineffective for this specific drug profile.preempt_rebuttal
211
The slide uses a table to contrast the solubility of different diazoxide forms to undermine the company's rationale for their specific formulation.expose_contradiction
212
The slide uses a combination of a simulated PK model and a clinical study figure to challenge the necessity and efficacy of the DCCR tablet.expose_contradiction
213
The slide uses a 'claim-refutation' structure to dismantle the target company's product differentiation narrative.preempt_rebuttal
214
The slide uses molecular weight calculations to expose that DCCR is simply a salt form of diazoxide, implying the price premium is unjustified.expose_contradiction
215
The slide uses a Q&A format to validate the thesis that MDCalc is a key driver for off-label drug substitution.illustrate_case
216
Uses direct quotes from interviews to undermine the value proposition of the target company's product.preempt_rebuttal
217
Uses expert quotes to debunk the necessity of the company's proprietary drug formulation.expose_contradiction
218
Uses FDA label excerpts to highlight the contradiction between the drug's design and its actual usage/safety profile.expose_contradiction
219
The slide uses Q&A transcripts to highlight internal knowledge of safety risks and potential for generic substitution.expose_contradiction
220
The slide uses a quote from a trial investigator to expose a potential safety oversight in study design.expose_contradiction
221
The slide uses a Q&A transcript format to build a case against the drug's physical formulation.expose_contradiction
222
Uses a combination of product imagery and user-generated content (Facebook post) to critique the competitor's dosing complexity.expose_contradiction
224
The slide uses a Q&A transcript format to highlight negative sentiment from former employees.expose_contradiction
225
The slide uses direct quotes from an expert consultation to undermine the credibility of the drug's approval and market potential.expose_contradiction
226
The slide uses direct quotes from an ex-employee to build a case of corporate misconduct regarding clinical trial data.expose_contradiction
227
The slide uses a combination of a summary paragraph and a direct verbatim quote with highlighted sections.expose_contradiction
228
The slide uses a Q&A transcript format to highlight the alleged suppression of negative clinical trial results.expose_contradiction
229
The slide uses a Q&A format to highlight internal concerns regarding trial integrity and the potential for participant bias due to unblinding.expose_contradiction
230
The slide uses highlighted text to emphasize key criticisms (soft endpoints, cherry-picking, safety signals).expose_contradiction
231
The slide uses a Q&A transcript format to highlight potential safety data suppression.expose_contradiction
232
The slide uses a Q&A format to highlight potential corporate malfeasance regarding safety data reporting.expose_contradiction
233
The slide uses a Q&A transcript format to validate the activist's thesis regarding data manipulation and competitive threat.expose_contradiction
234
The slide uses a long, narrative-style headline that summarizes the ex-employee's critique, followed by a highlighted block quote.expose_contradiction
236
The slide uses a direct quote from an ex-employee to undermine the clinical value proposition of the drug.expose_contradiction
237
The slide uses a Q&A format to frame the contradiction between weight loss goals and diabetes risk.expose_contradiction
238
The slide uses direct quotes from an ex-employee to undermine the credibility of the company's clinical trial results.expose_contradiction
239
The slide uses a Q&A format to highlight specific concerns about data collection consistency and physiological noise (edema).expose_contradiction
241
The slide uses a quote to establish credibility and validate the activist's research findings.illustrate_case
242
The slide uses direct quotes from a Key Opinion Leader (KOL) to build a case against the drug's safety and market viability.name_villain
243
The slide uses a Q&A format to validate the primary claim made in the headline.expose_contradiction
244
The slide uses direct quotes to build a case of corporate malfeasance regarding safety disclosures.expose_contradiction
245
The slide uses a 'quote-summary' structure to undermine the company's launch narrative.expose_contradiction
247
The slide uses a Q&A transcript format to build a case against the safety of the drug Vykat.expose_contradiction
248
The slide uses a Q&A transcript format to highlight potential safety concerns and lack of transparency regarding trial outcomes.expose_contradiction
249
The slide uses direct quotes from a KOL to undermine the credibility of the clinical trial results.expose_contradiction
250
The slide uses direct quotes from a KOL to undermine the credibility of the clinical trial results.expose_contradiction
251
The slide uses a Q&A format to highlight inconsistencies in clinical trial reporting.expose_contradiction
252
The slide uses direct quotes from a KOL to undermine the company's marketing narrative.expose_contradiction
253
The slide uses a quote to undermine the credibility of the company's clinical trial data by highlighting the difference between controlled trial environments anexpose_contradiction
254
The slide uses direct quotes to frame the problem of insurance access as a deliberate strategy of 'playing chicken' by insurers.illustrate_case
255
The slide uses direct quotes to frame the company's actions as predatory and unethical.expose_contradiction
256
The slide uses direct quotes from a KOL to frame the company's town hall as an 'infomercial' that avoids difficult questions.expose_contradiction
257
The slide uses a Q&A format to present expert testimony that undermines the value proposition of the drug Vykat.expose_contradiction
259
The slide uses a 'Miller XR' moniker to highlight the perceived over-reliance on a single individual.expose_contradiction
260
The slide uses red boxes to highlight the name 'Jennifer Miller' across different study documents to emphasize her consistent involvement.expose_contradiction
261
The slide uses a quote to highlight potential ethical or professional concerns regarding a physician's promotion of a drug.expose_contradiction
262
The slide uses emotional imagery and anecdotal evidence to undermine the credibility of a key figure in the PWS space.name_villain
263
Includes a screenshot of a blog post and two photos of the doctor interacting with a child.illustrate_case
264
The slide uses direct quotes and expert testimony to build a case against the credibility of a key opinion leader (Miller).expose_contradiction
265
The slide uses a screenshot of a tweet as primary evidence to expose the subject's promotional behavior.expose_contradiction
266
Uses press release excerpts to establish a pattern of behavior or conflict of interest.expose_contradiction
267
The slide uses a combination of narrative text, a screenshot of a YouTube video, and snippets of press articles to build a case of poor judgment or questionableexpose_contradiction
268
The slide uses a direct quote to highlight a conflict of interest or professional disagreement regarding medical standards.expose_contradiction
269
The slide uses direct quotes from an Anthem VP to undermine the product's market viability.expose_contradiction
270
The slide uses highlighted text to emphasize key parts of the expert interview transcript.expose_contradiction
271
The slide uses direct quotes to expose the insurer's strategy of forcing generic/compounded substitution to save costs.expose_contradiction
272
The slide uses red arrows to connect the two associations to the town hall event flyer.illustrate_case
273
The slide uses expert quotes to undermine the perceived market opportunity for Soleno.expose_contradiction
274
The slide uses a Q&A transcript format to undermine the commercial viability of the drug.expose_contradiction
275
The slide uses direct quotes from a researcher to undermine the perceived positive sentiment of the drug.expose_contradiction
276
The slide uses a Q&A format to highlight the tension between corporate marketing pressure and scientific/ethical boundaries.expose_contradiction
277
The slide uses a Q&A format to highlight negative expert sentiment.expose_contradiction
278
The slide uses a Q&A format to highlight negative expert sentiment regarding commercial viability.preempt_rebuttal
279
The slide uses highlighted quotes from a former senior medical affairs employee to undermine the commercial viability of Vykat.expose_contradiction
281
The slide uses a 'villain/expert critique' format to undermine the target company's drug efficacy and pricing.expose_contradiction
282
The slide uses highlighted text to draw attention to key negative sentiments from the KOL.expose_contradiction
283
The slide uses direct quotes from a KOL to build a case against the safety profile of the drug.name_villain
284
The slide uses a Q&A transcript format to highlight expert skepticism and safety concerns.expose_contradiction
285
The slide uses a Q&A format to present expert opinion as evidence of safety risks.expose_contradiction
286
The slide uses highlighted text to emphasize key concerns about cardiac risk, genetic subtypes, and the drug's unknown mechanism of action.expose_contradiction
287
The slide highlights a potential safety risk identified by a KOL regarding the drug's mechanism of action.expose_contradiction
288
The slide uses direct quotes from a KOL to build a case against the safety profile of the drug Vykat, specifically highlighting the risk of electrolyte depletioexpose_contradiction
289
Uses Q&A format to highlight expert skepticism and safety concerns.expose_contradiction
290
The slide uses a Q&A format to highlight allegations of 'artificial enrollment' and data manipulation.expose_contradiction
291
Uses direct quotes from a trial investigator to undermine the validity of clinical trial data.expose_contradiction
292
The slide uses a Q&A format to highlight allegations of data manipulation and lack of clinical efficacy.expose_contradiction
293
The slide uses direct quotes and Q&A transcripts to undermine the credibility of the drug's launch prospects.expose_contradiction
294
The slide uses direct quotes from a KOL to undermine the company's narrative of drug efficacy and market adoption.expose_contradiction
295
The slide uses a Q&A transcript format to highlight negative sentiment from a key opinion leader.expose_contradiction
296
The slide uses a Q&A transcript format to provide primary source evidence of a product flaw.expose_contradiction
297
The slide uses Q&A transcripts to undermine the competitive advantage of the Vykat tablet formulation.expose_contradiction
298
The slide uses a Q&A format to highlight the investigator's lack of enthusiasm and low patient uptake.expose_contradiction
299
The slide uses direct Q&A transcripts to highlight the investigator's negative sentiment and concerns about patient safety (diabetes/hyperglycemia).expose_contradiction
300
The slide uses a Q&A format to highlight specific quotes from a trial investigator regarding drug safety concerns.expose_contradiction
301
The slide uses a Q&A format to highlight specific allegations of misconduct regarding clinical trial reporting.expose_contradiction
302
The slide uses a Q&A format to highlight potential misconduct by the company.expose_contradiction
303
The slide uses a Q&A format to highlight alleged unethical behavior by Soleno regarding academic integrity and investigator relations.expose_contradiction
304
The slide uses a 'villain_critique' structure to undermine a competitor's clinical trial results by citing an expert's negative testimony.expose_contradiction
305
The slide uses direct quotes from a trial investigator to undermine the drug's market potential and clinical efficacy.expose_contradiction
306
The slide uses a Q&A format to present qualitative evidence from a trial investigator.expose_contradiction
307
The slide uses a Q&A format to highlight the investigator's skepticism.expose_contradiction
308
The slide uses direct quotes from a trial investigator to undermine the validity of clinical trial results.expose_contradiction
309
The slide uses a Q&A format to frame the investigator's critique of the drug's safety profile.expose_contradiction
310
The slide uses bolding and highlighting to emphasize negative feedback from a key opinion leader.expose_contradiction
311
The slide uses a Q&A format to document expert testimony regarding trial integrity.expose_contradiction
312
The slide uses a direct quote from an endocrinologist to cast doubt on the company's clinical data integrity.expose_contradiction
313
The slide uses a Q&A format to highlight the expert's skepticism about the company's reporting practices.expose_contradiction
314
The slide uses a Q&A format to highlight expert opinion against the subject drug (DCCR/Vykat).expose_contradiction
315
Includes verbatim Q&A transcripts highlighting the investigator's passive approach to patient recruitment.introduce_nominees
316
The slide uses Q&A transcripts to undermine the perceived market success of the drug.expose_contradiction
317
The slide uses direct quotes from a trial investigator to undermine the drug's clinical value and commercial prospects.expose_contradiction
318
The slide uses a 'quote-as-evidence' structure to undermine the clinical efficacy of the drug.expose_contradiction
319
The slide uses a Q&A transcript format to expose flaws in clinical trial integrity.expose_contradiction
320
The slide uses a Q&A format to present expert testimony from a trial investigator.expose_contradiction
321
The slide uses a Q&A transcript format to expose flaws in the clinical trial design regarding pill size.expose_contradiction
322
The slide uses a Q&A transcript format to undermine the company's product value proposition.expose_contradiction
323
The slide uses a combination of summary text and direct interview transcripts to highlight expert skepticism.expose_contradiction
324
The slide uses a Q&A format to highlight the failure of the trial's blinding protocol.expose_contradiction
325
The slide uses direct quotes from a pediatric endocrinologist to build a case against the drug's safety profile.expose_contradiction
326
The slide uses Q&A transcripts to expose the risks of the drug and the burden of monitoring.expose_contradiction
327
The slide uses a bolded summary paragraph at the top, followed by a detailed Q&A transcript with yellow highlighting on key quotes.expose_contradiction
328
The slide uses a Q&A transcript format to support the thesis that the competitor product is unnecessary or inferior.cite_precedent
330
Includes direct Q&A transcripts from a trial investigator/endocrinologist.preempt_rebuttal
331
The slide uses direct quotes from an endocrinologist/KOL to undermine the clinical trial results.expose_contradiction
332
The slide uses a direct quote from an endocrinologist to undermine the primary endpoint of a clinical trial.expose_contradiction
333
The slide uses direct quotes from a trial investigator to undermine the company's value proposition.expose_contradiction
334
The slide uses direct quotes from a trial investigator to undermine the value proposition of the drug Vykat.expose_contradiction
335
The slide uses direct quotes from an interview to highlight the discrepancy between public promotion and private clinical reality.expose_contradiction
336
The slide uses a Q&A format to highlight the investigator's reluctance and admission of clinical risks.expose_contradiction
337
Uses direct quotes from an investigator to undermine the credibility of clinical trial data.expose_contradiction
338
The slide uses a Q&A transcript format to highlight potential misclassification of adverse events in a clinical trial.expose_contradiction
340
The slide presents a transcript of an expert consultation call to undermine the market potential of Vykat.expose_contradiction
341
The slide uses direct quotes from an expert consultation to undermine the product's value proposition.expose_contradiction
342
The slide uses a Q&A format to highlight the expert's negative sentiment toward the drug's efficacy and the company's investor materials.expose_contradiction
343
The slide presents a direct challenge to the commercial viability of 'Vykat' by highlighting a physician's preference for a cheaper, off-label alternative.expose_contradiction
344
The slide uses a Q&A format to validate the expert's critique of the product's form factor.diagnose_problem
345
The slide uses expert quotes to undermine the company's claims regarding the drug's safety profile and market potential.expose_contradiction
346
The slide uses highlighted text to emphasize critical quotes from medical experts.expose_contradiction
347
The slide uses a combination of summary text and verbatim Q&A transcripts to highlight negative sentiment.expose_contradiction
348
The slide presents interview transcripts highlighting a lack of buzz at a major industry conference.summarize
349
The slide uses direct quotes to undermine the market potential and safety profile of the drug.expose_contradiction
350
The slide presents a Q&A format highlighting expert skepticism regarding the drug's safety profile and market relevance.expose_contradiction
351
The slide uses direct quotes to highlight physician skepticism and lack of awareness regarding the drug's trial flaws.expose_contradiction
352
The slide uses direct quotes to highlight the expert's negative sentiment toward the drug and the clinical trial methodology.expose_contradiction
355
The slide uses a Q&A format to build a case for market substitution risk.expose_contradiction
356
The slide uses a Q&A transcript format to highlight low adoption rates and physician skepticism.expose_contradiction
357
The slide uses a 'villain' narrative by framing a specific researcher (Jennifer Miller) and patient families as a 'cult' driving artificial demand.expose_contradiction
358
The slide uses a Q&A format to highlight skepticism among medical professionals regarding a drug's marketing presentation.expose_contradiction
359
The slide uses direct quotes to undermine the credibility of the company's sales representatives and the drug's market reception.expose_contradiction
360
The slide uses a summary headline followed by a verbatim quote with key phrases highlighted in yellow.expose_contradiction
361
The slide uses direct quotes from a pediatric endocrinologist to undermine the viability of a drug (Vykat/diazoxide).expose_contradiction
362
The slide uses direct quotes from a pediatric endocrinologist to highlight concerns about the clinical management of diabetes risk associated with the drug.expose_contradiction
363
The slide highlights a discrepancy between the company's sales pitch and clinical best practices as perceived by an expert.expose_contradiction
364
The slide uses verbatim quotes from a consultation call to highlight a discrepancy between the company's risk management (handouts) and the physician's expectatexpose_contradiction
365
The slide uses direct quotes from an endocrinologist to undermine the product's differentiation and pricing justification.expose_contradiction
366
The slide uses direct quotes to highlight a potential discrepancy between marketing claims and clinical reality.expose_contradiction
367
The slide highlights a direct contradiction between the company's marketing (Vykat) and expert clinical opinion.expose_contradiction
368
The slide highlights the physician's skepticism and the administrative hurdles faced with the drug Vykat.introduce_nominees
369
The slide highlights the endocrinologist's reluctance to prescribe the drug, noting that patient pressure was a primary driver for his involvement.expose_contradiction
370
The slide uses a Q&A format to expose that the drug's popularity is manufactured by advocacy groups rather than medical demand.expose_contradiction
371
The slide uses a Q&A transcript format to expose potential conflicts of interest between a company (Soleno) and a patient association.expose_contradiction
372
The slide uses a Q&A transcript format to highlight potential misinformation or manipulation by study investigators regarding drug efficacy timelines.expose_contradiction
373
The slide uses direct quotes to frame the expert's skepticism and clinical concerns about the drug's safety profile.expose_contradiction
374
The slide uses a Q&A transcript format to expose potential flaws in clinical trial methodology and physician sentiment.expose_contradiction
375
The slide uses highlighted text to emphasize key phrases from the expert's transcript.illustrate_case
376
The slide uses Q&A transcripts to undermine the value proposition of the company's product.expose_contradiction
377
The slide uses a Q&A format to expose a gap in the company's support infrastructure.expose_contradiction
378
The slide uses a 'before-after' narrative structure to expose the contradiction between the physician's initial interest and his clinical assessment.expose_contradiction
379
The slide uses a direct quote from a pediatric endocrinologist to undermine the drug's clinical value.expose_contradiction
380
The slide uses direct quotes to expose the contradiction between the physician's knowledge of drug inefficacy and their continued prescription behavior.expose_contradiction
381
The slide uses direct quotes from an expert consultation to contrast grassroots patient enthusiasm with professional indifference.expose_contradiction
382
The slide uses a Q&A transcript format to highlight the physician's frustration and lack of guidance from the manufacturer.illustrate_case
383
The slide presents a quote from an anonymous pediatric endocrinologist criticizing Dr. Miller's influence and medical recommendations.name_villain
384
The slide uses a pull-quote style to highlight the expert's hesitation and lack of full support.expose_contradiction
385
The slide highlights a potential safety concern raised by an expert, specifically regarding pre-diabetic and obese patients.expose_contradiction
386
The slide presents a Q&A format where the expert questions the company's motives and the clinical rationale for their product.expose_contradiction
387
The slide uses Q&A transcripts to undermine the credibility of the company's marketing claims.expose_contradiction
388
The slide uses a combination of summary text and direct interview transcripts to build a case against the drug's adoption.introduce_nominees
389
The slide uses a Q&A format to highlight expert skepticism regarding the drug's necessity and cost-effectiveness.expose_contradiction
390
The slide highlights a negative expert opinion on a drug being repurposed for PWS.expose_contradiction
391
The slide uses a 'quote-sandwich' technique: a summary paragraph followed by verbatim Q&A transcripts with highlighted key phrases.expose_contradiction
392
The slide uses direct quotes and Q&A excerpts to build a case against the safety of the drug Vykat in the context of PWS treatment.cite_precedent
393
The slide uses highlighted text to emphasize key concerns about Vykat's safety profile and Miller's private skepticism.expose_contradiction
394
The slide uses expert interview transcripts to undermine the value proposition of the drug Vykat.expose_contradiction
395
The slide uses a Q&A format to highlight the physician's reluctance to prescribe Vykat and their familiarity with the risks of diazoxide.expose_contradiction
396
The slide uses direct quotes from a pediatric endocrinologist to undermine the company's commercial narrative.expose_contradiction
397
The slide uses direct quotes to build a case against the company's commercial execution.illustrate_case
398
The slide uses a Q&A format to expose the contradiction between the drug's intended use and its actual clinical viability.expose_contradiction
399
The slide uses direct quotes from an expert consultation to illustrate market resistance.diagnose_problem
400
The slide uses a combination of summary bullet points and verbatim Q&A transcripts to highlight the expert's negative assessment.expose_contradiction
401
The slide uses a direct quote to undermine the perceived value of the drug.expose_contradiction
402
The slide highlights a potential competitive threat to Vykat from generic diazoxide.expose_contradiction
403
The slide highlights a contradiction between the drug's intended use and its physiological impact on a vulnerable patient population.expose_contradiction
404
The slide uses a summary paragraph followed by a direct quote, highlighting the expert's negative sentiment.expose_contradiction
405
The slide uses direct quotes from an expert consultation to highlight the drug's perceived lack of efficacy and the barrier of administrative burden.illustrate_case
407
The slide presents a summary of an expert interview, highlighting the endocrinologist's preference for GLP-1s over Vykat for PWS patients.illustrate_case
408
The slide uses direct quotes from an endocrinologist to frame potential medical risks as a barrier to adoption.diagnose_problem
409
The slide uses direct quotes to build a narrative of expert doubt.illustrate_case
410
The slide uses Q&A transcripts to highlight the expert's skepticism regarding Vykat's value proposition.expose_contradiction
411
The slide uses a Q&A format to highlight the administrative burden and slow approval process for the drug Vykat.illustrate_case
412
The slide uses a Q&A transcript format to validate the claim of trial unblinding.expose_contradiction
413
The slide uses a Q&A format to present primary research findings from a consultation call.diagnose_problem
414
The slide uses Q&A transcript format to build credibility for the thesis that generic substitution is common practice among specialists.cite_precedent
415
Includes a Q&A transcript snippet highlighting anecdotal evidence.illustrate_case